Indeed, TLR9 activation via CPG-ODNs could provide protection from cancer by activating dendritic cells to stimulate innate immune responses, such as enhanced natural killer-mediated tumor killing, and the subsequent adaptive T cell and humoral immunity [43,44]. Here, TLR9 is linked to cancer.